Search PubMed⌕ Search

Biomedical subjects

V Jones

Publications and source records attributed to V Jones.

At least 55 records · Page 3Linked to original sources
PubMed1984

Synovial synthesis of rheumatoid factors and immune complex constituents in early arthritis.

Synovial synthesis of immune complex constituents and rheumatoid factors has been estimated in rheumatoid arthritis (RA) and in unclassifiable inflammatory arthritis (IA) and related to duration of symptoms. Within 6 months of onset of symptoms both RA and IA patients synthesised (or trapped) immune complexes locally. However, local synthesis of the rheumatoid factors was almost exclusive to RA patients and mainly in patients with symptoms of more than 6 months' duration. Thus all arthritis patients may respond immunologically to an initial trigger in the affected joint but only RA patients develop localised chronic autoimmunity later.

Adolescent↗
PubMed1981

[Anatomy of the upper abdomen seen by real-time ultrasound].

Ultrasound has made it possible to identify major blood vessels of the abdomen. The identification of these vascular structures has been facilitated with the use of gray's scale ultrasound but more so with real time ultrasound. The identification of these vascular structures as well as the advantages that they present in identifying abdominal viscera will be discussed.

Abdomen↗
PubMed1979

Cytogenetic analysis of the sensitivity to anti-viral and anti-cell growth activities of human fibroblast interferon in aneuploid human tumor cell lines. Brief report.

The ability of human fibroblast interferon to suppress colony formation and papovavirus T-antigen expression in six human tumor cell lines did not appear to correlate with their content of chromosomes 16 and 21. Additional factors or chromosomes may be involved in the manifestation of interferon action in aneuploid cells.

Aneuploidy↗
PubMed1978

Treatment and survival on advanced breast cancer.

The final results of a clinical trial comparing endocrine with cytotoxic drug treatment for advanced breast cancer were analysed. Although cytotoxic treatment gave a significantly higher response rate with a remission duration comparable to that obtained with endocrine treatment, the sequence in which the two treatments were given did not appear to influence survival--except possibly in women with rapidly progressing disease, when cytotoxic treatment is preferred.

Antineoplastic Agents↗
PubMed1977

Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer.

Ninety-two women with advanced breast cancer were allocated at random to receive either cytotoxic or endocrine treatment. Out of 45 women included in the cytotoxic treatment group, 22 (49%) achieved complete or partial remission of their disease, whereas of the 47 included in the endocrine treatment group, only 10 (21%) achieved such remission. Significantly longer survival times in the cytotoxic treatment group were most apparent among premenopausal women, 75% of such patients responding to cytotoxic drugs (median survival 46 weeks) compared with only 11% benefiting from ovarian ablation (median survival 12 weeks). In postmenopausal women with predominantly soft-tissue disease, however, additive hormonal treatment with tamoxifen produced remission rates and survival times equivalent to those produced by cytotoxic drugs.

Adenocarcinoma↗